In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for VB-111. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of VB-111 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [2]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [3]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for DE-098. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of DE-098 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [4]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [5]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for 2-aminophenoxazine-3-one. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of 2-aminophenoxazine-3-one through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [6]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-103. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of APG-103 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for F61F12. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of F61F12 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [8]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for ISIS 17020. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 17020 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[1], [9]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cystine/glutamate transporter (SLC7A11) is a therapeutic target for L-glutamic acid. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of L-glutamic acid through regulating the expression of Cystine/glutamate transporter (SLC7A11).			[10], [11]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11).			[10], [12]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Almotriptan malate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Almotriptan malate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [14]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aminophenazone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Aminophenazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [15]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amiodarone hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Amiodarone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [16]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amitriptyline hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Amitriptyline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [17]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amodiaquine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Amodiaquine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [18]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Anastrozole. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Anastrozole through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [19]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apalutamide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Apalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [20]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apixaban. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Apixaban through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [21]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Atorvastatin calcium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Atorvastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Azelastine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Azelastine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [23]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Benzyl alcohol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Benzyl alcohol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [24]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Beraprost. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Beraprost through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [25]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Brigatinib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Brigatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [26]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Bromfenac. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Bromfenac through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Buprenorphine hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Buprenorphine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [28]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [29]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Caffeine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Caffeine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Capsaicin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Capsaicin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Carbamazepine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Carbamazepine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cefaloridine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cefaloridine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Celecoxib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Celecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [34]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cerivastatin sodium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cerivastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cisapride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cisapride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [35]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Clozapine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Clozapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [36]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyclophosphamide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cyclophosphamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [37]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dabrafenib mesylate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Dabrafenib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [38]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Desloratadine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Desloratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [39]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dexibuprofen. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Dexibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diazepam. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Diazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diclofenac sodium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Diclofenac sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diethylstilbestrol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Diethylstilbestrol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [43]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diltiazem hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Diltiazem hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eltrombopag olamine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Eltrombopag olamine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enasidenib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Enasidenib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [46]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enzalutamide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Enzalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol acetate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Estradiol acetate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol cypionate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Estradiol cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol valerate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Estradiol valerate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eszopiclone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Eszopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ethinyl estradiol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ethinyl estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [49]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Fluvastatin sodium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Fluvastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Glasdegib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Glasdegib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [51]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Halofantrine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Halofantrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ibuprofen. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ifosfamide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ifosfamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [37]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Irbesartan. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Irbesartan through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [49]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Istradefylline. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Istradefylline through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [53]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ixazomib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ixazomib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [55]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketorolac. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ketorolac through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [56]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lansoprazole. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Lansoprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [57]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lapatinib ditosylate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Lapatinib ditosylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [58]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Levomilnacipran. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Levomilnacipran through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lidocaine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Lidocaine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loperamide hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Loperamide hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loratadine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Loratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lorlatinib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Lorlatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Losartan potassium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Losartan potassium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [63]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lovastatin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Lovastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mefenamic acid. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mefenamic acid through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [65]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mephenytoin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mephenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [66]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mestranol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mestranol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [67]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Methadone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Methadone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [68]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mirtazapine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mirtazapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Montelukast sodium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Montelukast sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Morphine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Morphine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [70]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mycophenolate mofetil. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naloxone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Naloxone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [28]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naproxen. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Naproxen through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicardipine hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Nicardipine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicotine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Nicotine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nilotinib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Nilotinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ombitasvir. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ombitasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Omeprazole. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Omeprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pazopanib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Pazopanib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pentamidine isethionate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Pentamidine isethionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Perphenazine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Perphenazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenobarbital. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Phenobarbital through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [79]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenprocoumon. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Phenprocoumon through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenytoin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Phenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pioglitazone hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Pioglitazone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Piroxicam. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Piroxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pitavastatin calcium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Pitavastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Propofol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Propofol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinidine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Quinidine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinine sulfate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Quinine sulfate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Repaglinide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Repaglinide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Riociguat. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Riociguat through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rofecoxib. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Rofecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rosiglitazone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Rosiglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selegiline hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Selegiline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selexipag. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Selexipag through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Simvastatin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Simvastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sitagliptin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Sitagliptin through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [91]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfadiazine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Sulfadiazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfamethoxazole. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Sulfamethoxazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [93]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfinpyrazone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Sulfinpyrazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tazarotene. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Tazarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [94]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tegafur. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Tegafur through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Temazepam. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Temazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [96]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Terbinafine hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Terbinafine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone cypionate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Testosterone cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone enanthate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Testosterone enanthate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone undecanoate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Testosterone undecanoate through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Thalidomide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Thalidomide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tolbutamide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Tolbutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [98]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Torasemide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Torasemide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [99]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Treprostinil. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Treprostinil through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [100]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trifarotene. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Trifarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [101]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethadione. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Trimethadione through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [102]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [103]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Troglitazone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Troglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [104]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Velpatasvir. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Velpatasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [105]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Verapamil hydrochloride. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Verapamil hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [106]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Vortioxetine hydrobromide. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Vortioxetine hydrobromide through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [107]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Voxilaprevir. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Voxilaprevir through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [105]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Warfarin sodium. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Warfarin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zafirlukast. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Zafirlukast through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [103]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zidovudine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Zidovudine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zopiclone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Zopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [108]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BMS-298585. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BMS-298585 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [109]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BNP-1350. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BNP-1350 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [110]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CKD-501. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of CKD-501 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [111]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CYT-387. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of CYT-387 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [112]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dasabuvir. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Dasabuvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [113]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Domperidone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Domperidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [114]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for DRF-2593. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of DRF-2593 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [111]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for EMD-128130. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of EMD-128130 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [115]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAS-17177. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of LAS-17177 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [116]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAU-7b. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of LAU-7b through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [117]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [118]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for NSC-122758. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of NSC-122758 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [119]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for QLT-091001. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of QLT-091001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [119]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rivoglitazone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Rivoglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [120]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-2014. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AZD-2014 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [121]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for GSK-1278863. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of GSK-1278863 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [122]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for TAK-652. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of TAK-652 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [123]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AG-1549. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AG-1549 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [124]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-9496. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AZD-9496 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [125]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for H3B-6545. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of H3B-6545 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [126]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for M-813. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of M-813 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [127]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for MK-0822. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of MK-0822 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [128]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Antipyrine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Antipyrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyamemazine. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cyamemazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [129]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Paraoxon. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Paraoxon through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [130]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ABT-001. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ABT-001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [131]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ADD-3878. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ADD-3878 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [111]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aleglitazar. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Aleglitazar through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [132]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ML-3000. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ML-3000 through regulating the expression of Cytochrome P450 2C8 (CYP2C8).			[13], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for HIF-1alpha. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of HIF-1alpha through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for IT-101. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of IT-101 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [135]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for 2-Methoxyestradiol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of 2-Methoxyestradiol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PT2385. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of PT2385 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [137]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ENMD-1198. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ENMD-1198 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [138]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for EZN-2968. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of EZN-2968 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [139]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PX-478. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of PX-478 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [140]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [141]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 175510. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 175510 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298697. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298697 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298699. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298699 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298700. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298700 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298701. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298701 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298702. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298702 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298711. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298711 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298712. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298712 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298743. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298743 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298744. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298744 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298745. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298745 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298746. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ISIS 298746 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A).			[133], [143]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Mecasermin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Mecasermin through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [145]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Somatomedin-1. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Somatomedin-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[141], [144]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Teprotumumab. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Teprotumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [146]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Rinfabate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Rinfabate through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [147]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMG 479. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AMG 479 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [148]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AXL-1717. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AXL-1717 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [149]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cixutumumab. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cixutumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [150]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for MM-141. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of MM-141 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [151]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for R1507. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of R1507 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [152]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for TT-100. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of TT-100 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [153]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for VPI-2690B. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of VPI-2690B through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [154]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AEW-541. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AEW-541 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [155]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BIIB 022. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BIIB 022 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [156]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cyclolignan picropodophyllin. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cyclolignan picropodophyllin through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [157]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for FPI-1434. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of FPI-1434 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [158]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for HF-0299. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of HF-0299 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [159]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for RG-7010. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of RG-7010 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [160]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for ATL-1101. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of ATL-1101 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [161]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS-695735. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BMS-695735 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [162]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [163]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [164]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AG 1024. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AG 1024 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [165]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Alpha-D-Mannose. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Alpha-D-Mannose through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [166]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [166]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AZD3463. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AZD3463 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [167]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [163]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Fucose. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Fucose through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [168]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK-1838705A. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of GSK-1838705A through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [169]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK1511931. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of GSK1511931 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [170]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for JB-1. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of JB-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [171]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for NVP-ADW742. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of NVP-ADW742 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [168]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for PQ401. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of PQ401 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [172]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AVE-1642. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of AVE-1642 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [173]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Figitumumab. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Figitumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [174]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for KW-2450. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of KW-2450 through regulating the expression of Insulin-like growth factor I receptor (IGF1R).			[144], [175]